B. Riley Financial’s Post

Redx Pharma PLC (AIM:REDX) (AIM: REDX), a clinical-stage biotechnology company focusing on developing novel therapeutics for fibrotic disease and cancer, said it plans to de-list from AIM to re-register as a private limited company.  Chair, Dr Jane Griffiths, said the decision to exit the LSE's junior market had been a unanimous one as she voiced frustration over the company's current valuation - echoing sentiment across the sector. "Despite completing some of the largest AIM capital raises for biotech companies in recent years, Redx is still liquidity-constrained on AIM," Griffiths said. "As a result, we believe our current market valuation is not reflective of our track record or future potential and is not conducive to raising the level of capital required for our growing clinical portfolio. More at #Proactive #ProactiveInvestors #biotechnology #RedXpharma http://ow.ly/HHlP105oaGB

$175M in new funding is no small thing for a biotech startup... Aktis Oncology’s $175M Series B round, led by RA Capital Management with participation from RTW Investments, LP, Janus Henderson Group PLC, and strategic investors like Eli Lilly and Company and Bristol Myers Squibb, is a significant development in the radiopharmaceutical space. This funding positions Aktis to advance its lead candidate, AKY-1189, targeting Nectin-4 in solid tumors. The involvement of industry leaders and prominent investors reflects the growing confidence in targeted radiopharmaceuticals as a next-generation cancer treatment, signaling a larger shift in oncology toward precision therapies that aim to improve efficacy and minimize side effects. Matthew Roden Dave Ricks Giovanni Caforio Merck MRL Ventures Fund LLC Rob Davis Peter Kolchinsky Roderick Wong Ali Dibadj T. Rowe Price Rob Sharps Avidity Partners #Biotech #Radiopharmaceuticals #OncologyInnovation #PrecisionMedicine #CancerResearch #Innovation #VentureCapitalists #VCFunding #ClinicalTrials https://lnkd.in/ej9fvC-U https://lnkd.in/evi2Qntw https://lnkd.in/eHCjFbyS

Thoughts on this? >> Boundless Bio seeks $88M in IPO as it runs two Ph1 cancer trials >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical

Here’s the follow up post about one of our former clients. Well done Dr. Ricarda Finnern! #business #biotech #Germany #biotechnology #research #consulting

🎄 𝑫𝒂𝒚 7: 𝑬𝒎𝒆𝒓𝒈𝒆𝒏𝒄𝒆 𝑻𝒉𝒆𝒓𝒂𝒑𝒆𝒖𝒕𝒊𝒄𝒔 🎄 This smaller business is investing in innovation and “best in class” technology for development of novel oncology focused Antibody-Drug Conjugates (ADC). ✨ The business was acquired by Eli Lilly and Company in 2022 due to their impressive pipeline for approx. $12m worth of shares. It is now a wholly owned subsidiary. ✨ In 2021 Emergence Therapeutics received $87m worth of funding for advancement of existing ADC R&D projects and pipeline development. ✨ Last year, Hatem Azim joined as Chief Medical Officer from the highly successful French business, Pierre Fabre. The experience that Hatem brings will no doubt help accelerate their innovative projects! ✨ Synaffix B.V and Emergence announced last year that they were entering into a licensing agreement for ADC Technology platforms worth up to $360m I’ve heard a lot of hype about the ADC Therapeutics market this year, so keep your ears and eyes open for Emergence Therapeutics! #pharma #therapeutics #ADCs #biotech #letspivot

Thoughts on this? >> 4P-Pharma raises €15M; Oncotelic Therapeutics sells rights to cancer assets >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #pharma #productmarketing

Thoughts on this? >> Boundless Bio seeks $88M in IPO as it runs two Ph1 cancer trials >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma

📈 Big Moves in Biotech! Ono Pharmaceutical seals a transformative $2.4B deal, acquiring Deciphera Pharmaceuticals to revolutionize its cancer drug portfolio. 🎯 Ono bags an approved game-changer Qinlock, a potential blockbuster vimseltinib, and key commercial infrastructure to strengthen its US presence. Deciphera shareholders get a 70% premium windfall 💰 Despite global uncertainties, companies are moving ahead, innovating, and investing in treatments. This move signals strong confidence in the cancer therapy market's future.🧬 What are your thoughts on this strategic acquisition? #Biotech #CancerResearch #PharmaceuticalIndustry

🌱💡 Empowering Cancer Treatment's Future: Tissue Dynamics and OrganoSpheres Revolutionize Health with Organoid Robotics and AI! #EmpoweringCancerTreatment #OrganoidRobotics #AIInnovation #HealthRevolution #TissueDynamics #OrganoSpheres #FutureOfHealthcare #CuttingEdgeTech

In February, the Nasdaq Biotechnology Index gained 1%, the SPDR S&P Biotech ETF spiked 12%, and the S&P Biotechnology Select Industry Index soared 16%. - Novo Nordisk’s (⬆3%) parent Novo Holdings acquired CDMO Catalent for US$ 16.5 bn. - FDA okayed Iovance Biotherapeutics, Inc.’s (⬆113%) T-cell therapy for skin cancer. - Eli Lilly and Company (⬆14%) posted a 28% increase in Q4 revenue. View our interactive dashboard: https://lnkd.in/g7miavBu Read more at: https://lnkd.in/gfpmZFyV #PipelineProspector February 2024 - Pharma & Biotech Monthly Recap by PharmaCompass.com #stockmarket #biotech #pharmaceuticalindustry #sales #pharmanews #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #Pharmaceuticals #pharmacompass